203 related articles for article (PubMed ID: 37287269)
1. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.
Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Der Walt AV; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Morgado YB; Spitaleri D; Pesch VV; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H;
Neurodegener Dis Manag; 2023 Aug; 13(4):215-221. PubMed ID: 37287269
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Blanco Morgado Y; Spitaleri D; van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H
Mult Scler; 2023 Feb; 29(2):221-235. PubMed ID: 36433775
[TBL] [Abstract][Full Text] [Related]
3. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.
Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; di Cantogno EV
Neurodegener Dis Manag; 2023 Oct; 13(5):261-268. PubMed ID: 37535336
[TBL] [Abstract][Full Text] [Related]
4. The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.
Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
Neurodegener Dis Manag; 2022 Dec; 12(6):285-293. PubMed ID: 35920065
[TBL] [Abstract][Full Text] [Related]
5. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist TP; Coyle PK; Dangond F; Alexandri N; Galazka A
Neurodegener Dis Manag; 2022 Dec; 12(6):303-310. PubMed ID: 36017797
[TBL] [Abstract][Full Text] [Related]
6. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets.
Schmierer K; Wiendl H; Oreja-Guevara C; Centonze D; Chudecka A; Roy S; Boschert U
Neurodegener Dis Manag; 2023 Feb; 13(1):15-21. PubMed ID: 36545912
[TBL] [Abstract][Full Text] [Related]
7. [Comments on the GLIMPSE study on evaluating the efficacy of the drug cladribine in tablets in routine clinical practice in comparison with other tablet drugs for the pathogenetic treatment of multiple sclerosis].
Boyko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7. Vyp. 2):73-77. PubMed ID: 35912560
[TBL] [Abstract][Full Text] [Related]
8. Cladribine (Mavenclad) for multiple sclerosis.
Med Lett Drugs Ther; 2019 Jul; 61(1577):118-120. PubMed ID: 31381552
[No Abstract] [Full Text] [Related]
9. Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Jack D; Vermersch P
Neurodegener Dis Manag; 2022 Dec; 12(6):295-301. PubMed ID: 36017780
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
Lizak N; Hodgkinson S; Butler E; Lechner-Scott J; Slee M; McCombe PA; Shaw C; Skibina O; Vucic S; Shuey N; Barnett MH; Parratt J; Butzkueven H; Jack D; Fabris J; Kalincik T
Mult Scler; 2021 Mar; 27(3):465-474. PubMed ID: 32530363
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
Pinheiro B; Guerreiro R; Costa J; Miguel LS
J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
[No Abstract] [Full Text] [Related]
12. The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.
Butzkueven H; Moore N; Aydemir A; Sõnajalg J; Bezemer I; Korhonen P; Sabidó M;
Curr Med Res Opin; 2022 Jul; 38(7):1167-1176. PubMed ID: 35357268
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.
Brownlee WJ; Haghikia A; Hayward B; Waser N; Kayaniyil S; Khan Z; Duncan J; Millar S; Harty GT
Mult Scler Relat Disord; 2023 Aug; 76():104791. PubMed ID: 37343465
[TBL] [Abstract][Full Text] [Related]
14. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.
Rauma I; Viitala M; Kuusisto H; Atula S; Sipilä JOT; Ryytty M; Soilu-Hänninen M; Järvinen E
Mult Scler Relat Disord; 2022 May; 61():103755. PubMed ID: 35483129
[TBL] [Abstract][Full Text] [Related]
15. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
[TBL] [Abstract][Full Text] [Related]
16. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
[TBL] [Abstract][Full Text] [Related]
17. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.
Mankinen P; Lundström T; Soini E; Sumelahti ML; Ruutiainen J; Niskala U; Järvinen E
Adv Ther; 2020 Feb; 37(2):800-818. PubMed ID: 31873868
[TBL] [Abstract][Full Text] [Related]
18. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
[TBL] [Abstract][Full Text] [Related]
19. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.
Brownlee W; Amin A; Ashton L; Herbert A
Mult Scler Relat Disord; 2023 Nov; 79():104951. PubMed ID: 37639781
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis.
Rau D; Müller B; Übler S
Adv Ther; 2023 Dec; 40(12):5547-5556. PubMed ID: 37776477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
